Table 2.
Hormonal levels of participants of the PrEParadas DDI substudy during the short-term assessment according to FHT use
| Hormone | noFHTa (n = 12) |
sFHTb (n = 18) |
P valuec |
|---|---|---|---|
| Baselined | |||
| Oestradiol (pg/mL) | 43.0 (37.7–47.2) | 39.4 (33.8–56.8) | 1 |
| Testosterone (ng/dL) | 421.6 (260.5–543.5) | 507.6 (84.4–594.5) | 1 |
| Prolactin (ng/mL) | 6.25 (5.12–8.07) | 7.85 (5.55–12.33) | 0.09 |
| SHBG (nmol/L) | 48.5 (41.91–57.0) | 65.8 (51.1–92.4) | 0.02 |
| Week 4 | |||
| Oestradiol (pg/mL) | 38.9 (34.8–44.5) | 46.0 (39.8–69.6) | 0.03 |
| Week 12 | |||
| Oestradiol (pg/mL) | 44.3 (32.8–48.6) | 56.8 (43.2–65.4) | 0.05 |
| Testosterone (ng/dL) | 424.1 (315.4–682.1) | 363.1 (152.5–617.7) | 0.42 |
| Prolactin (ng/mL) | 7.55 (6.68–10.00) | 9.40 (6.98–11.78) | 0.32 |
| SHBG (nmol/L) | 41.6 (31.1–65.6) | 85.4 (54.8–140.0) | 0.003 |
Bold type indicates statistical significance.
a
On PrEP only, no FHT at baseline and short-term PK.
b
On PrEP plus FHT on short-term PK.
c
Wilcoxon rank sum test comparing noFHT versus sFHT participants.
d
noFHT and sFHT participants evaluated at enrolment and screening visits, respectively.